Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Oikonomou, Eftychia ^a   Koc, Michal ^b   Sourkova, Vladimira ^b   Andera, Ladislav ^b   Pintzas, Alexander ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CA; PLX 4720; TANESPIMYCIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; FURAN DERIVATIVE; INDOLE DERIVATIVE; PIK3CA PROTEIN, HUMAN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL STRAIN CACO 2; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME REPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; NONHUMAN; ONCOGENE; CELL STRAIN HT29; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CACO-2 CELLS; CELL LINE, TUMOR; FLOW CYTOMETRY; FURANS; HT29 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; INDOLES; MICROSCOPY, FLUORESCENCE; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIDINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79959594837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021632     Document Type: Article

References (42)

1. Oikonomou E, Makrodouli E, Evagelidou M, Joyce T, Probert L, et al. (2009) BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia 11: 1116-1131.
2. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, et al. (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5 1476-4598-5-2 [pii];10.1186/1476-4598-5-2 [doi].
3. Adams JM, Cory S, (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337 1210220 [pii];10.1038/sj.onc.1210220 [doi].
4. Lowe SW, Cepero E, Evan G, (2004) Intrinsic tumour suppression. Nature 432: 307-315 nature03098 [pii];10.1038/nature03098 [doi].
5. Ziegler U, Groscurth P, (2004) Morphological features of cell death. News Physiol Sci 19: 124-128.
6. Roninson IB, Broude EV, Chang BD, (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4: 303-313 10.1054/drup.2001.0213 [doi];S1368-7646(01)90213-4 [pii].
7. Fang JY, Richardson BC, (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327 S1470-2045(05)70168-6 [pii];10.1016/S1470-2045(05)70168-6 [doi].
8. Schwartsmann G, Di Leone LP, Dal PF, Roesler R, (2005) MAPK pathway activation in colorectal cancer: a therapeutic opportunity for GRP receptor antagonists. Lancet Oncol 6: 444-445 S1470-2045(05)70226-6 [pii];10.1016/S1470-2045(05)70226-6 [doi].
9. Tominaga K, Higuchi K, Sasaki E, Suto R, Watanabe T, et al. (2004) Correlation of MAP kinases with COX-2 induction differs between MKN45 and HT29 cells. Aliment Pharmacol Ther 20 Suppl 1: 143-150 10.1111/j.1365-2036.2004.01986.x [doi];APT1986 [pii].
10. Michl P, Downward J, (2005) Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 43: 1133-1139 10.1055/s-2005-858638 [doi].
11. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163 10.1038/5517 [doi].
12. MacFarlane M, (2003) TRAIL-induced signalling and apoptosis. Toxicol Lett 139: 89-97 S0378427402004228 [pii].
13. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, et al. (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276: 46639-46646 10.1074/jbc.M105102200 [doi];M105102200 [pii].
14. Suliman A, Lam A, Datta R, Srivastava RK, (2001) Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and-independent pathways. Oncogene 20: 2122-2133 10.1038/sj.onc.1204282 [doi].
15. Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, et al. (2005) Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer 92: 736-742 6602387 [pii];10.1038/sj.bjc.6602387 [doi].
16. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE, (2001) MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 276: 16484-16490 10.1074/jbc.M010384200 [doi];M010384200 [pii].
17. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, et al. (2005) Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 280: 22856-22867 M412483200 [pii];10.1074/jbc.M412483200 [doi].
18. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105: 3041-3046 0711741105 [pii];10.1073/pnas.0711741105 [doi].
19. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430 nature08902 [pii];10.1038/nature08902 [doi].
20. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221 S0092-8674(09)01626-2 [pii];10.1016/j.cell.2009.12.040 [doi].
21. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435 nature08833 [pii];10.1038/nature08833 [doi].
22. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, et al. (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A 103: 57-62 0609973103 [pii];10.1073/pnas.0609973103 [doi].
23. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, et al. (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277: 39858-39866 10.1074/jbc.M206322200 [doi];M206322200 [pii].
24. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410 10.1038/nature01913 [doi];nature01913 [pii].
25. Roberts ML, Drosopoulos KG, Vasileiou I, Stricker M, Taoufik E, et al. (2006) Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. Int J Cancer 118: 616-627 10.1002/ijc.21386 [doi].
26. Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, et al. (2007) Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer 97: 73-84 6603835 [pii];10.1038/sj.bjc.6603835 [doi].
27. da Rocha DS, Friedlos F, Light Y, Springer C, Workman P, et al. (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65: 10686-10691 65/23/10686 [pii];10.1158/0008-5472.CAN-05-2632 [doi].
28. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA, (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50 S1368-7646(07)00076-3 [pii];10.1016/j.drup.2007.11.003 [doi].
29. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, et al. (2001) Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell 12: 2629-2645.
30. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, et al. (2010) PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28: 15s,suppl.
31. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362 nature04304 [pii];10.1038/nature04304 [doi].
32. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, et al. (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3 10.1371/journal.pone.0003065 [doi].
33. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, et al. (2010) PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Res 70: 6804-6814 0008-5472.CAN-10-0409 [pii];10.1158/0008-5472.CAN-10-0409 [doi].
34. Vaculova A, Hofmanova J, Soucek K, Kozubik A, (2006) Different modulation of TRAIL-induced apoptosis by inhibition of pro-survival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Lett 580: 6565-6569 S0014-5793(06)01312-3 [pii];10.1016/j.febslet.2006.11.004 [doi].
35. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, et al. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293 0008-5472.CAN-08-4765 [pii];10.1158/0008-5472.CAN-08-4765 [doi].
36. Rychahou PG, Murillo CA, Evers BM, (2005) Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 138: 391-397 S0039-6060(05)00268-0 [pii];10.1016/j.surg.2005.05.012 [doi].
37. Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, et al. (2011) Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin Cancer Res pp. 1078-0432 CCR-10-2530 [pii];10.1158/1078-0432.CCR-10-2530 [doi].
38. Vasilevskaya IA, O'Dwyer PJ, (2005) 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol 70: 580-589 S0006-2952(05)00349-7 [pii];10.1016/j.bcp.2005.05.018 [doi].
39. Siegelin MD, Habel A, Gaiser T, (2009) 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol Dis 33: 243-249 S0969-9961(08)00260-X [pii];10.1016/j.nbd.2008.10.005 [doi].
40. Wertz IE, Dixit VM, (2010) Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ 17: 14-24 cdd2009168 [pii];10.1038/cdd.2009.168 [doi].
41. Park WS, Lee JH, Shin MS, Park JY, Kim HS, et al. (2001) Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 121: 1219-1225 S0016508501611478 [pii].
42. Jin Z, McDonald ER III, Dicker DT, El-Deiry WS, (2004) Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279: 35829-35839 10.1074/jbc.M405538200 [doi];M405538200 [pii].